The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: An analysis of residual risk attributable to lipid profile in acute coronary syndrome.

Jesús Millán Núnez-Cortes, Juan Pedro Botet Montoya, Xavier Pintó Salas, Antonio Hernández Mijares, Vincent J. Carey, Michel P. Hermans, Frank M. Sacks, Jean Charles Fruchart

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

The R3i Foundation (Residual Risk Reduction Initiative), an independent, multinational and academic organization, is conducting the REALIST (Residual Risk, Lipids and Standard Therapies) study in 40 centers in different countries. This is a retrospective epidemiological study, designed to provide new data on the residual risk of major coronary events attributable to lipid abnormalities in patients receiving the current standard treatment. The initial results are expected in mid 2010, and the overall results at the end of 2010. © 2010 SEEN.
Original languageEnglish
Pages (from-to)38-47
JournalEndocrinologia y Nutricion
Volume58
Issue number1
DOIs
Publication statusPublished - 1 Jan 2011

Keywords

  • Dyslipidemia
  • Ischemic heart disease
  • Residual risk

Fingerprint Dive into the research topics of 'The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: An analysis of residual risk attributable to lipid profile in acute coronary syndrome.'. Together they form a unique fingerprint.

  • Cite this

    Millán Núnez-Cortes, J., Montoya, J. P. B., Salas, X. P., Mijares, A. H., Carey, V. J., Hermans, M. P., Sacks, F. M., & Fruchart, J. C. (2011). The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: An analysis of residual risk attributable to lipid profile in acute coronary syndrome. Endocrinologia y Nutricion, 58(1), 38-47. https://doi.org/10.1016/j.endonu.2010.10.004